You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

386 Results
Drug
Other Name(s): Gleevec®
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Dec 2024
Drug
Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Nov 2024
Drug
Other Name(s): Sarclisa®
Mar 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Feb 2025
Drug
Other Name(s): Velcade®
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Apr 2025
Document
Document

Pages